Media headlines about Auris Medical Holding AG (NASDAQ:EARS) have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Auris Medical Holding AG earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 100 out of 100, indicating that recent news coverage is extremely likely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

EARS has been the topic of a number of research reports. Roth Capital initiated coverage on Auris Medical Holding AG in a report on Thursday, April 13th. They issued a “buy” rating and a $4.50 price objective on the stock. ValuEngine downgraded Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Auris Medical Holding AG has a consensus rating of “Hold” and a consensus target price of $3.42.

Shares of Auris Medical Holding AG (NASDAQ:EARS) traded up 3.766% during midday trading on Friday, reaching $0.799. The company’s stock had a trading volume of 141,333 shares. The company has a 50-day moving average price of $0.78 and a 200-day moving average price of $0.83. Auris Medical Holding AG has a 12 month low of $0.60 and a 12 month high of $5.45. The firm’s market cap is $35.42 million.

Auris Medical Holding AG (NASDAQ:EARS) last posted its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.08. Equities analysts expect that Auris Medical Holding AG will post ($0.72) earnings per share for the current year.

WARNING: “Auris Medical Holding AG (NASDAQ:EARS) Getting Somewhat Favorable News Coverage, Analysis Finds” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/04/somewhat-positive-news-coverage-extremely-likely-to-impact-auris-medical-holding-ag-nasdaqears-stock-price-updated-updated-updated.html.

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Insider Buying and Selling by Quarter for Auris Medical Holding AG (NASDAQ:EARS)

Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.